ArticleInfection & chemotherapy2025
The Mortality of Colistin Monotherapy
Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy inAntimicrobial agents and chemotherapy · 2026Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Retrospective Analysis of the Molecular Links Among Clustered Cases ofChina CDC weekly · 2026Article
- Clinical Relevance of Antimicrobial Susceptibility Testing Methods in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9-12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant MATERIALS AND
methodsThis retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9-12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan-Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.
resultsThe unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06-0.55) for 7-day mortality and 0.53 (95% CI,-0.29-0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11-0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07-0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.
conclusionCombining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.